These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

231 related items for PubMed ID: 9872332

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Wnt signalling in human breast cancer: expression of the putative Wnt inhibitor Dickkopf-3 (DKK3) is frequently suppressed by promoter hypermethylation in mammary tumours.
    Veeck J, Bektas N, Hartmann A, Kristiansen G, Heindrichs U, Knüchel R, Dahl E.
    Breast Cancer Res; 2008; 10(5):R82. PubMed ID: 18826564
    [Abstract] [Full Text] [Related]

  • 5. The extracellular matrix protein ITIH5 is a novel prognostic marker in invasive node-negative breast cancer and its aberrant expression is caused by promoter hypermethylation.
    Veeck J, Chorovicer M, Naami A, Breuer E, Zafrakas M, Bektas N, Dürst M, Kristiansen G, Wild PJ, Hartmann A, Knuechel R, Dahl E.
    Oncogene; 2008 Jan 31; 27(6):865-76. PubMed ID: 17653090
    [Abstract] [Full Text] [Related]

  • 6. Promoter hypermethylation of TMS1, BRCA1, ERalpha and PRB in serum and tumor DNA of invasive ductal breast carcinoma patients.
    Mirza S, Sharma G, Prasad CP, Parshad R, Srivastava A, Gupta SD, Ralhan R.
    Life Sci; 2007 Jul 04; 81(4):280-7. PubMed ID: 17599361
    [Abstract] [Full Text] [Related]

  • 7. Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers.
    Takahashi Y, Miyoshi Y, Takahata C, Irahara N, Taguchi T, Tamaki Y, Noguchi S.
    Clin Cancer Res; 2005 Feb 15; 11(4):1380-5. PubMed ID: 15746036
    [Abstract] [Full Text] [Related]

  • 8. Expression of BRCA1 protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene.
    Wang C, Horiuchi A, Imai T, Ohira S, Itoh K, Nikaido T, Katsuyama Y, Konishi I.
    J Pathol; 2004 Feb 15; 202(2):215-23. PubMed ID: 14743504
    [Abstract] [Full Text] [Related]

  • 9. Aberrant methylation of the BRCA1 CpG island promoter is associated with decreased BRCA1 mRNA in sporadic breast cancer cells.
    Rice JC, Massey-Brown KS, Futscher BW.
    Oncogene; 1998 Oct 08; 17(14):1807-12. PubMed ID: 9778046
    [Abstract] [Full Text] [Related]

  • 10. Hypermethylation in histologically distinct classes of breast cancer.
    Bae YK, Brown A, Garrett E, Bornman D, Fackler MJ, Sukumar S, Herman JG, Gabrielson E.
    Clin Cancer Res; 2004 Sep 15; 10(18 Pt 1):5998-6005. PubMed ID: 15447983
    [Abstract] [Full Text] [Related]

  • 11. Epigenetic factors controlling the BRCA1 and BRCA2 genes in sporadic ovarian cancer.
    Chan KY, Ozçelik H, Cheung AN, Ngan HY, Khoo US.
    Cancer Res; 2002 Jul 15; 62(14):4151-6. PubMed ID: 12124354
    [Abstract] [Full Text] [Related]

  • 12. Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast.
    Kominsky SL, Argani P, Korz D, Evron E, Raman V, Garrett E, Rein A, Sauter G, Kallioniemi OP, Sukumar S.
    Oncogene; 2003 Apr 03; 22(13):2021-33. PubMed ID: 12673207
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Aberrant promoter methylation and silencing of laminin-5-encoding genes in breast carcinoma.
    Sathyanarayana UG, Padar A, Huang CX, Suzuki M, Shigematsu H, Bekele BN, Gazdar AF.
    Clin Cancer Res; 2003 Dec 15; 9(17):6389-94. PubMed ID: 14695139
    [Abstract] [Full Text] [Related]

  • 16. CpG methylation within the 5' regulatory region of the BRCA1 gene is tumor specific and includes a putative CREB binding site.
    Mancini DN, Rodenhiser DI, Ainsworth PJ, O'Malley FP, Singh SM, Xing W, Archer TK.
    Oncogene; 1998 Mar 05; 16(9):1161-9. PubMed ID: 9528858
    [Abstract] [Full Text] [Related]

  • 17. Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients.
    Dulaimi E, Hillinck J, Ibanez de Caceres I, Al-Saleem T, Cairns P.
    Clin Cancer Res; 2004 Sep 15; 10(18 Pt 1):6189-93. PubMed ID: 15448006
    [Abstract] [Full Text] [Related]

  • 18. Reduced Brca1 protein expression in 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-induced rat mammary carcinomas.
    Okochi E, Miyamoto K, Wakazono K, Shima H, Sugimura T, Ushijima T.
    Mol Carcinog; 2002 Aug 15; 34(4):211-8. PubMed ID: 12203372
    [Abstract] [Full Text] [Related]

  • 19. Haplo-insufficiency of BRCA1 in sporadic breast cancer.
    Staff S, Isola J, Tanner M.
    Cancer Res; 2003 Aug 15; 63(16):4978-83. PubMed ID: 12941823
    [Abstract] [Full Text] [Related]

  • 20. Hypermethylation of the breast cancer-associated gene 1 promoter does not predict cytologic atypia or correlate with surrogate end points of breast cancer risk.
    Bean GR, Ibarra Drendall C, Goldenberg VK, Baker JC, Troch MM, Paisie C, Wilke LG, Yee L, Marcom PK, Kimler BF, Fabian CJ, Zalles CM, Broadwater G, Scott V, Seewaldt VL.
    Cancer Epidemiol Biomarkers Prev; 2007 Jan 15; 16(1):50-6. PubMed ID: 17220331
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.